Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT03733626 · ClinicalTrials.gov registry record · NA

Clinical Outcomes Associated With the Use of ViviGen® for the Treatment of Lumbar Degenerative Disc Disease

A NA study, sponsored by Corewell Health East.

Completed
Registry status
NA
Development phase
46
Enrollment target

NCT03733626 is a NA study that has completed, run by Corewell Health East. The registered enrollment target is 46 participants.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT03733626, a NA study, has completed, sponsored by Corewell Health East.

COMPLETED
Registry status
NA
Development phase
46 participants
Enrollment target

Study Summary

The objective of this study is to perform a prospective, randomized, controlled clinical trial to compare radiographic fusion rates and patient reported outcomes, including pain and function preoperatively and postoperatively, using Depuy ViviGen® Cellular Bone Matrix mixed with cortical/cancellous allograft in conjunction with an approved Depuy Synthes pedicle screw system compared to autograft mixed with cortical/cancellous allograft in conjunction with the same DePuy Synthes pedicle screw system used for a one or two - level posterolateral lumbar fusion.

Interventions

  • COMBINATION_PRODUCT ViviGen® Cellular Bone Matrix with DePuy Synthes Spinal Pedicle screw system
  • COMBINATION_PRODUCT Local Bone Autologous Bone Graft with DePuy Synthes Spinal pedicle screw system

Trial Details

FieldValue
Enrollment Target 46 participants
Start Date 2019-03-19
Est. Completion 2024-06-25
Phase NA

Sponsor

Corewell Health East

106 total trials

What the Registry Record Tells You About NCT03733626

The ClinicalTrials.gov registry entry for NCT03733626 describes a study currently listed as completed, categorized as NA. The registered enrollment target is 46 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Corewell Health East, which has 106 total studies on file at ClinicalTrials.gov.

The record links to 0 conditions, and to 2 interventions - of which ViviGen® Cellular Bone Matrix with DePuy Synthes Spinal Pedicle screw system is the first listed.

NCT03733626 reports 0 study locations.

Frequently Asked Questions

What is clinical trial NCT03733626 about?

NCT03733626 is a clinical study titled "Clinical Outcomes Associated With the Use of ViviGen® for the Treatment of Lumbar Degenerative Disc Disease". The objective of this study is to perform a prospective, randomized, controlled clinical trial to compare radiographic fusion rates and patient reported outcomes, including pain and function preoperatively and postoperatively, using Depuy ViviGen® Cellular Bone Matrix mixed with cortical/cancellous ...

What is the current status of trial NCT03733626?

This trial is currently completed. It is a NA study. The enrollment target is 46 participants. The study started on 2019-03-19. Estimated completion is 2024-06-25.

What interventions are being tested in trial NCT03733626?

The interventions under investigation include: ViviGen® Cellular Bone Matrix with DePuy Synthes Spinal Pedicle screw system (COMBINATION_PRODUCT), Local Bone Autologous Bone Graft with DePuy Synthes Spinal pedicle screw system (COMBINATION_PRODUCT).

Who is sponsoring clinical trial NCT03733626?

This trial is sponsored by Corewell Health East, which has 106 total clinical trials registered on ClinicalTrials.gov.

Data sourced from official public datasets. See our methodology for details. Retrieved and formatted by PlainTrial Editorial

Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.